AA
ACAD icon

Ancora Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Ancora Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7,000
Closed -$223K – 1222
2016
Q3 		$223K Buy
+7,000
New +$237K 0.02% 457

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Ancora Advisors's ACAD Position: Q4 2016 in Review

Ancora Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q4 2016, closing a stake of 7,000 shares — an estimated $223K sold.

Ancora Advisors first reported a position in ACAD in Q3 2016 and held it in 1 quarter. The position peaked at $223K in Q3 2016. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

  • Ancora Advisors reported no remaining Acadia Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Ancora Advisors sold 7,000 Acadia Pharmaceuticals shares in Q4 2016, an estimated $223K.
  • Ancora Advisors first reported a position in Acadia Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Ancora Advisors's Acadia Pharmaceuticals position peaked at $223K in Q3 2016.
  • 225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on Ancora Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.